Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice

NCT06857942 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06857942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06857942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Recruiting
Start date
March 19, 2025
Completion date
May 31, 2028
Enrollment
200 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

overweight or obesity, psoriasis